How should SEC chromatography peptide aggregates be read on a research chromatogram?
An SEC chromatogram maps hydrodynamic volume under one mobile phase. In ideal size exclusion, species that cannot enter the pores travel in the interstitial volume and elute at the void. Species that sample the pore volume elute later, near the total permeation time of a small-marker solute. A peptide oligomer is expected earlier than the monomer only when both sit inside the fractionation window and neither is adsorbed. Short research peptides often fail that test on antibody-range media. Pores sized for a large protein and its multimers can place a monomer of a few kilodaltons and a compact dimer near total permeation. One symmetrical peak then does not prove that a small oligomer is absent. Record the void marker, the total-permeation marker, and the peptide position against both. Elution after the total-permeation marker shows non-ideal retention. Elution in the void may be a true excluded species or insoluble material, which should be described as such rather than integrated as a dissolved oligomer. Globular-protein calibration does not turn elution time into true molar mass. Peptide shape rarely matches the standards, and residual interaction shifts the apparent value. The defensible label is early-eluting species with an apparent hydrodynamic volume larger than the main component under the stated method. Identity is left to mass spectrometry or light scattering. Area percent is not mass percent when chromophores differ, and it ignores material that never eluted. State the wavelength, commonly near 214 to 220 nm for the peptide bond, or 280 nm only where aromatic residues justify it, plus the reporting threshold and whether solvent peaks were excluded. Physicochemical comparability between a proposed rituximab biosimilar and the originator has been published as a multi-attribute comparison, not as a single free-standing number (PMID:23649935). A research peptide lot needs the same rule for size: no acceptance statement without the column, the mobile phase, and the integration rules.
Why do residual silanols distort a peptide SEC-HPLC profile?
Residual silanols on silica-based SEC-HPLC packings often destroy a pure size separation. Where silanols are deprotonated and the peptide carries the opposite charge, electrostatic attraction delays elution, increases tailing, and can lower the eluted peak area. Hydrophobic contact does the same for aromatic or aliphatic sequences, even when the pore size is theoretically right. The diagnostic is a retention time that moves when ionic strength or a small organic co-solvent changes, or a peak that elutes after the total-permeation marker. Until that interaction is suppressed, or the result is labelled non-ideal, apparent size is not trustworthy. Cyclodextrin has been added to the SEC-HPLC mobile phase to mitigate interactions of proteins, peptides, or their impurities with residual silanols on commercial columns (PMID:29946984). If a laboratory adopts that additive, it becomes part of the method identity. A trace run with cyclodextrin cannot be compared, peak for peak, with a trace run without it. The certificate should name the additive rather than imply a generic SEC purity. Salt level, pH, and any organic modifier decide whether an early peak is excluded by size or is simply less retained than a main component that is sticking. Polymer-based hydrophilic packings reduce silanol artefacts but do not end adsorption. Hydrogen bonding and hydrophobic patches remain possible, especially for cyclic peptides and sequences carrying tryptophan, phenylalanine, or long aliphatic side chains. A blank after the sample, in the same sample solvent, shows whether a late peak is carry-over. Poor elution of early species beside a symmetrical main peak is the failure mode that area percent hides: adsorbed aggregate never appears, and the eluted monomer is reported as nearly the whole sample. A mass-balance comparison belongs next to the area table. Without it, a report of no aggregate detected may only mean that no aggregate eluted.
Which early peaks are oxidation-linked aggregates, and which are only apparent?
Protein oxidation can induce protein:protein aggregation, so an early SEC peak after oxidative stress is not automatically a reversible oligomer (PMID:18760979). The orthogonal test changes with that distinction. A non-covalent oligomer may dissociate in organic solvent, at another pH, or on dilution, and it may vanish in a reversed-phase method whose mobile phase is built to denature. A covalent cross-link stays large under those conditions and should show a mass shift, not only an SEC shoulder. A certificate that uses one label for both, without the split, does not separate synthesis quality from solution history. Forced-degradation work on recombinant human granulocyte colony-stimulating factor has highlighted apparent degradation forms, and the quality-control risk of reading every stressed peak as a true product change (PMID:31533024). Apparent forms matter for peptide SEC in the same way. Dissolution solvent, pH, time in solution, and contact with metal or air can create species that were not in the dry solid. A lot file should state whether SEC was run on the material as received, after a defined dissolution interval, or after a deliberate stress. An early peak seen only after a long hold in a poor solvent is a solution-stability observation, not a release attribute of the unopened vial. A high-molecular-weight peak can also be a covalent synthesis variant. Studies of cleavage-efficient 2A peptides for monoclonal antibody expression in CHO cells frame cleavage efficiency as the difference between released chains and larger fusion species (PMID:25621616). The interpretation rule is what transfers to a synthetic peptide lot. An early peptide peak may be an uncleaved, branched, or cross-linked synthesis product rather than a self-associated monomer. Retention time cannot choose. A collected fraction examined by mass spectrometry can. Until then, the honest label is early-eluting species, identity not assigned, with elution volume recorded against the main component.
What does protein-folding SEC show about additives, aggregates and renaturation?
Protein-folding size-exclusion chromatography has been applied to in vitro refolding with simultaneous purification of recombinant human parathyroid hormone 1-34, including the role of solution additives in aggregates and renaturation (PMID:26472319). That is a process experiment. The column separates unfolded or aggregated polypeptide from smaller additives, and from species of different hydrodynamic size, while refolding is under way. Additives are present because they change that balance. The trace describes a dynamic refolding mixture. It does not describe the oligomer content of a lyophilised research solid tested later in another solvent. For lot testing the rule is stricter. Any additive in the analytical solution, including buffer ion, chaotrope, cyclodextrin, organic co-solvent, or a residual synthesis counter-ion, can shift the aggregate population the column sees. The certificate must name the sample solvent and the peptide concentration in that solvent. Two lots run at different concentrations, or one in acetate buffer and one in water, are not a comparison of the solids. Dilution can dissociate weak oligomers, so a more dilute preparation can show a smaller early peak on SEC with no difference in the dry material. Record the flow rate and the column volume as well. A peak that looks early on a short column may be only partially resolved from the void, and a slow flow can sharpen a peptide separation while increasing the time during which a non-covalent oligomer can dissociate or adsorb. Renaturation language stays inside the experiment that measured it. An additive effect reported for parathyroid hormone 1-34 on a folding column is not evidence about another sequence, and it is not a statement about any catalogue item used outside that method. Where PF-SEC is a preparative step before release testing, the batch record should keep the process chromatogram apart from the release chromatogram, each with its column, flow, and additive list. A process yield trace is not a quantitative aggregate assay. Yield, resolution from additives, and the area of an early process peak answer different questions. Only an analytical method with a stated mass-balance check answers the lot-release question.
Which orthogonal records should accompany an SEC aggregate result?
Elution time is not molar mass. Multi-angle light scattering coupled to ion-exchange chromatography has been used to characterise proteins by reporting molar mass on a separation that is not organised by size (PMID:29720692). Light scattering assigns mass from the scattered signal and the concentration measurement, whether the peak left an ion-exchange column or a size-exclusion column. A late peak can still be large if silanols delayed it. An early peak can be an excluded particle rather than a peptide multimer. Where SEC coupled to multi-angle light scattering is available, it is the direct check on the same size-based separation. Two-dimensional and four-dimensional liquid chromatography-mass spectrometry have streamlined characterisation of an antibody-drug conjugate because one chromatographic trace under-describes a heterogeneous sample (PMID:31621311). For a research peptide the proportionate step is to collect the early fraction, or to couple a compatible size separation to mass spectrometry, and to test whether the mass is a monomer multiple, a covalent adduct, or an unrelated impurity. Reversed-phase area percent does not settle it. Acidic organic phases often dissociate non-covalent oligomers, so a high reversed-phase result can sit beside a real SEC early peak. Infliximab solutions have been studied under different temperature and dilution conditions (PMID:29287266). Heat-induced fibrillation of BclXL (PMID:23714425) and amyloid-beta fibrillogenesis examined with Hsp60 (PMID:27474204) are large-assembly pathways. An SEC trace can include only the fraction that remains dissolved and reaches the bed; material held on a filter or frit is outside the integral. Peptide dendrons have been evaluated as thermal-stability amplifiers for immunoglobulin G1 (PMID:28880521). That evaluation is a reminder, for method design only, that matrix architecture belongs in the record whenever heat is a variable. Record solution and column temperature, concentration, hold time, filtration, and matrix. Do not copy an antibody numerical limit onto a short peptide. For an Australian research lot, the file is complete only when those conditions sit with the chromatogram, the mass-balance note, and a statement that the result documents the tested solution for laboratory use.
Frequently asked questions
Does a high reversed-phase HPLC purity mean peptide aggregates are absent?
No. Reversed-phase methods commonly use acidic organic mobile phases that dissociate non-covalent oligomers, so the main-peak area can look high while an aqueous SEC run still shows an early species. SEC and reversed-phase HPLC answer different questions: hydrodynamic size in the stated aqueous method, versus hydrophobic retention of species that survive that mobile phase. A research file should report them as separate attributes, each with its method identity.
Why can a peptide elute after the total-permeation marker?
Elution after a small-molecule total-permeation marker means the peptide is retained by something other than sieving. Residual silanols, hydrophobic contact, or hydrogen bonding are typical causes on SEC-HPLC columns. Cyclodextrin has been reported as a mobile-phase additive that mitigates interactions of proteins, peptides, or impurities with residual silanols (PMID:29946984). Until the interaction is controlled, the elution time must not be converted into an apparent molar mass.
Can SEC miss fibrils and other large aggregates?
Yes. SEC reports species that stay dissolved and reach the column bed. Heat-induced fibrillation, as described for BclXL, and fibrillogenesis pathways studied for amyloid-beta, can produce material that a filter, frit, or bed retains (PMID:23714425; PMID:27474204). A clear void region after filtration is then a result on the filtrate, not on the whole sample. The record should note filtration, any haze, and that insoluble mass was outside the chromatogram.
Is protein-folding SEC the same as a release aggregate test?
No. Protein-folding SEC has been used to refold and purify recombinant human parathyroid hormone 1-34 while additives act on aggregates and renaturation (PMID:26472319). That trace describes a refolding mixture on a process column. A release test on a finished research solid uses a defined analytical method, a named sample solvent and concentration, and a mass-balance check. The two chromatograms should be filed separately so a process yield is not read as lot purity.
What should an Australian research-lot file include with an SEC result?
Include the column and its fractionation range, mobile phase and any additive such as cyclodextrin, detection wavelength, sample solvent, concentration, solution and column temperature, hold time, filtration, void and total-permeation markers, the area table, and a mass-balance note. State whether early peaks were identified by mass spectrometry or light scattering, or left unassigned. Do not import an antibody aggregate limit. The result documents the tested solution for research traceability only.
References
- PMID:18760979 — Protein:protein aggregation induced by protein oxidation — J Chromatogr B Analyt Technol Biomed Life Sci — 2008
- PMID:23649935 — Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab — BioDrugs — 2013
- PMID:23714425 — Heat-induced fibrillation of BclXL apoptotic repressor — Biophys Chem — 2013
- PMID:25621616 — Cleavage efficient 2A peptides for high level monoclonal antibody expression in CHO cells — MAbs — 2015
- PMID:26472319 — In vitro refolding with simultaneous purification of recombinant human parathyroid hormone (rhPTH 1-34) from Escherichia coli directed by protein folding size exclusion chromatography (PF-SEC): implication of solution additives and their role on aggregates and renaturation — Anal Bioanal Chem — 2016
- PMID:27474204 — Hsp60, amateur chaperone in amyloid-beta fibrillogenesis — Biochim Biophys Acta — 2016
- PMID:28880521 — Peptide Dendrons as Thermal-Stability Amplifiers for Immunoglobulin G1 Monoclonal Antibody Biotherapeutics — Bioconjug Chem — 2017
- PMID:29287266 — Stability of infliximab solutions in different temperature and dilution conditions — J Pharm Biomed Anal — 2018
- PMID:29720692 — Coupling Multi Angle Light Scattering to Ion Exchange chromatography (IEX-MALS) for protein characterization — Sci Rep — 2018
- PMID:29946984 — Use of Cyclodextrin as a Novel Agent in the SEC-HPLC Mobile Phase to Mitigate the Interactions of Proteins or Peptide or their Impurities with the Residual Silanols of Commercial SEC-HPLC Columns with Improved Separation and Resolution — Pharm Res — 2018
- PMID:31533024 — Apparent degradation forms of rhG-CSF under forced conditions: Insights for better quality-control of bioproducts — Anal Biochem — 2019
- PMID:31621311 — Streamlined Characterization of an Antibody-Drug Conjugate by Two-Dimensional and Four-Dimensional Liquid Chromatography/Mass Spectrometry — Anal Chem — 2019
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
